1-methyl-2-phenylindole is a synthetic indole derivative that has been investigated for its potential pharmacological properties. It has been reported to exhibit various biological activities, including antioxidant, anti-inflammatory, and anticancer effects. The synthesis of 1-methyl-2-phenylindole typically involves the condensation of phenylhydrazine with 2-acetyl-1-methylpyrrole. The compound is often studied as a lead compound for the development of new drugs, particularly in the areas of neurology and oncology. Its structural features, including the indole ring and phenyl substituent, contribute to its ability to interact with various biological targets. 1-methyl-2-phenylindole has shown promise in preclinical studies for the treatment of conditions such as Alzheimer's disease, Parkinson's disease, and cancer. Further research is ongoing to evaluate its therapeutic potential and safety profile in humans.'
| ID Source | ID |
|---|---|
| PubMed CID | 77095 |
| CHEMBL ID | 1545735 |
| SCHEMBL ID | 214075 |
| MeSH ID | M0510495 |
| Synonym |
|---|
| BIDD:GT0516 |
| unii-ie3ub978ia |
| ie3ub978ia , |
| nsc 63793 |
| einecs 222-618-1 |
| nsc-63793 |
| 2-phenyl-n-methylindole |
| 3558-24-5 |
| 1-methyl-2-phenylindole |
| 1h-indole, 1-methyl-2-phenyl- |
| nsc63793 |
| indole, 1-methyl-2-phenyl- |
| inchi=1/c15h13n/c1-16-14-10-6-5-9-13(14)11-15(16)12-7-3-2-4-8-12/h2-11h,1h |
| 1-methyl-2-phenylindole, 99% |
| NCIOPEN2_002836 |
| 1-methyl-2-phenyl-1h-indole |
| AF-963/00522046 |
| smr000543310 |
| MLS001215074 |
| STK202660 |
| AC-10577 |
| M0733 |
| AKOS001426229 |
| NCGC00246339-01 |
| n-methyl-2-phenylindole |
| A822887 |
| BBL012866 |
| HMS2857M05 |
| BP-13058 |
| FT-0608050 |
| AB00775587-01 |
| SCHEMBL214075 |
| J-504920 |
| 1-methyl-2-phenyl-1h-indol |
| 1-methyl-2-phenyl-indole |
| DTXSID5063073 |
| 1-methyl-2-phenyl-1h-indole # |
| CHEMBL1545735 |
| n-methyl-2-phenyl-indole |
| mfcd00022892 |
| AS-59068 |
| AC8408 |
| SY038925 |
| n-methyl-2-phenyl indole |
| 2-phenyl-1-methylindole |
| AMY23168 |
| EN300-20675 |
| CS-W015261 |
| Z104479722 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.1313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| GLS protein | Homo sapiens (human) | Potency | 5.6234 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 70.7946 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 1.0000 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1372210 | Inhibition of CYP19A1 (unknown origin) at 50 uM preincubated with NADPH followed by DBF substrate addition after 30 mins by fluorescence based assay relative to control | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1. |
| AID1372212 | Induction of QR1 activity in mouse Hepa-1c1c7 cells assessed as induction ratio at 50 uM after 48 hrs by MTT assay relative to control | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||